Cell Fusion

Cell Fusion describes the process of combining two or more cells to create hybrid cells containing genetic material and cellular components from multiple parent cells, enabling novel applications in therapeutics, research, and biotechnology. This technique can occur naturally through viral infection or be induced artificially using agents like polyethylene glycol, electrical pulses, or viral fusogenic proteins that disrupt cell membranes facilitating merger. Cell fusion technology has enabled breakthrough applications including hybridoma production for monoclonal antibody generation, creation of induced pluripotent stem cells, and development of cellular vaccines presenting multiple antigens.

The biopharmaceutical industry historically revolutionised antibody production through hybridoma technology, fusing antibody-producing B cells with immortal myeloma cells creating hybrid cell lines secreting specific monoclonal antibodies indefinitely. This foundational technique enabled the therapeutic antibody industry generating billions in annual revenue and transforming treatment paradigms across oncology, autoimmune diseases, and other therapeutic areas. Beyond hybridomas, cell fusion creates cellular vaccines where tumour cells fuse with dendritic cells, combining tumour antigens with immune-stimulating properties for cancer immunotherapy. Technical considerations involve optimising fusion efficiency, selecting fused cells from unfused parental populations, and stabilising hybrid genomes. Regulatory considerations address hybrid cell characterisation, genetic stability assessment, and adventitious agent testing ensuring safety of products derived from fused cells. As synthetic biology and cellular engineering advance, cell fusion principles inform development of novel cellular therapies while maintaining historical significance as enabling technology that launched the modern biologics era.